bullish
Yuhan Corp (000100 KS): R&D Endeavors Finally Began to Pay Back; Lazertinib to Drive Future Growth
283 Views21 Dec 2021 23:49
SUMMARY
- Yuhan Corp (000100 KS)'s R&D investments have started contributing to revenue through outlicensing deals. The company signed five out-licensing deals totaling KRW 4 trillion over the past three years.
- The company has launched one in-house developed oncology drug, lazertinib in Korea market this year. Other in-licensed marketed prescription drugs hold leadership positioning in their respective therapeutic areas.
- Outlicesing partner Janssen is expected to file new drug application to the US FDA in 2022. Yuhan is entitled for double-digit royalty on commercialization of Lazertinib in global market.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Yuhan Corp (000100 KS): Progress of Anti-Cancer Drug Leclaza Is the Main Growth Engine06 Dec 2022
- Yuhan Corp (000100 KS): R&D Endeavors Finally Began to Pay Back; Lazertinib to Drive Future Growth21 Dec 2021
x